Boutsikou et al. investigated the prognostic and predictive role of IFN-γ, tumor necrosis factor-alpha (TNF-α) and a panel of ILs in the peripheral blood of 26 NSCLC patients treated with pembrolizumab or nivolumab. This evidence concerns the gene TNF and non-small cell lung carcinoma.